Xavier Montalban
Overview
Explore the profile of Xavier Montalban including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
520
Citations
23081
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Carvajal R, Guananga-Alvarez D, Tur C, Esperalba J, Rodriguez-Barranco M, Rando-Segura A, et al.
Neurology
. 2025 Jan;
104(3):e210281.
PMID: 39819099
Background And Objectives: Hepatitis B vaccination (HBV) requires 6 months to complete and is recommended for patients with multiple sclerosis (PWMS), particularly those who are candidates for anti-CD20 therapy. However,...
12.
Villacieros-Alvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200362.
PMID: 39752619
Objectives: To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods: This...
13.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
14.
Giovannoni G, Boyko A, Correale J, Edan G, Freedman M, Montalban X, et al.
Mult Scler
. 2024 Dec;
31(1):44-58.
PMID: 39690897
Background: CLASSIC-MS explored long-term outcomes of patients treated with cladribine tablets. Objective: Assess long-term efficacy in patients previously enrolled in ORACLE-MS, a Phase III parent trial. Methods: ORACLE-MS included patients...
15.
Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, et al.
Neurodegener Dis Manag
. 2024 Dec;
14(6):193-201.
PMID: 39676554
No abstract available.
16.
Mongay-Ochoa N, Pareto D, Alberich M, Carbonell-Mirabent P, Valsasina P, Margoni M, et al.
Neurology
. 2024 Dec;
104(1):e210136.
PMID: 39666921
Background And Objectives: In multiple sclerosis (MS), brain reserve serves as a protective factor against cognitive impairment. Previous research has suggested a structural counterpart in the spine-spinal cord reserve-seemed to...
17.
Comabella M, Hegen H, Villar L, Rejdak K, Sao-Aviles A, Behrens M, et al.
J Neurol
. 2024 Dec;
272(1):26.
PMID: 39666032
Background And Objectives: The impact of viral infections on disease susceptibility and progression has predominantly been studied in patients with relapse-onset MS (RMS). Here, we determined immune responses to ubiquitous...
18.
Villacieros-Alvarez J, Lunemann J, Sepulveda M, Valls-Carbo A, Dinoto A, Fernandez V, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Dec;
12(1):e200340.
PMID: 39661937
Background And Objectives: The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis...
19.
Pinteac R, Soriano J, Matute-Blanch C, Lizcano J, Duarri A, Malhotra S, et al.
Clin Transl Med
. 2024 Dec;
14(12):e70125.
PMID: 39658520
No abstract available.
20.
Brownlee W, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, et al.
Ann Neurol
. 2024 Nov;
97(3):571-582.
PMID: 39605172
Objective: The 2017 McDonald criteria continued the separation of diagnostic criteria for relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) for historical, rather than biological, reasons. We aimed to...